SP-057

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameSP-057
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitorsImmunosuppressantsMatrix metalloproteinase inhibitors
TargetsMatrix metalloproteinaseTumor necrosis factor α
Therapy Area/IndicationsOsteoarthritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company Bristol-Myers Squibb Holdings Pharma Ltd Liability Company
Active IndicationsN/A
Inactive IndicationsOsteoarthritisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A